文献速递认知障碍与痴呆

临床前阿尔茨海默病与电子健康记录:平衡保密与照护

Preclinical Alzheimer Disease and the Electronic Health Record: Balancing Confidentiality and Care.
PubMed 文献 · Neurology · 2022-09-30

文章讨论美国《21世纪治愈法案》要求患者访问电子健康记录(EHR)后,临床前阿尔茨海默病(AD)状态作为敏感个人健康信息(PHI)面临的不当披露风险,包括污名化、歧视和可保险性改变,并指出目前缺乏充分法律保护,AD研究界需发展以参与者为中心的保密与披露伦理实践。

要点

  • 临床前AD的生物标志物在症状出现前即可识别,其状态属敏感PHI,不当披露可致污名、歧视和可保险性改变。
  • 美国《21世纪治愈法案》要求患者访问EHR诸多内容,增加了健康系统内外不当披露风险。
  • 临床前AD目前主要在研究中识别,临床诊断共识标准可能即将建立,但法律保护尚不充分。

核心结论

  • AD研究界必须继续发展以参与者为中心的保密与披露伦理实践,关注EHR中的敏感信息,以助转化至临床及健康系统和社会。

研究设计与样本

  • 本文为针对临床前AD与EHR保密及披露问题的论述性文章,未报告系统检索范围或样本量。

主要发现

  • 信息技术广泛用于临床研究和照护使PHI传播更广,美国《21世纪治愈法案》要求患者访问EHR许多内容。
  • 临床前AD状态属敏感PHI,不当披露可导致污名、歧视和可保险性改变等个人伤害。
  • 临床前AD目前主要在研究中识别,临床诊断共识标准可能即将建立,但 growing 人群尚缺充分法律保护。
  • 临床前AD试验产生的部分PHI具临床意义,需在照护环境中紧急评估和纵向监测。
  • AD研究者有义务尊重参与者敏感PHI保密并便利提供者获取必要信息,常需披露临床前AD状态。

临床怎么用

  • AD研究者应尊重参与者敏感PHI的保密性,并便利提供者获取必要信息,常需披露临床前AD状态。
  • AD研究界应继续发展以参与者为中心的保密与披露伦理实践,关注EHR中的敏感信息。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Because information technologies are increasingly used to improve clinical research and care, personal health information (PHI) has wider dissemination than ever before. The 21st Century Cures Act in the United States now requires patient access to many components of the electronic health record (EHR). Although these changes promise to enhance communication and information sharing, they also bring higher risks of unwanted disclosure, both within and outside of health systems. Having preclinical Alzheimer disease (AD), where biological markers of AD are identified before the onset of any symptoms, is sensitive PHI. Because of the melding of ideas between preclinical and "clinical" (symptomatic) AD, unwanted disclosure of preclinical AD status can lead to personal harms of stigma, discrimination, and changes to insurability. At present, preclinical AD is identified mainly in research settings, although the consensus criteria for a clinical diagnosis may soon be established. There is not yet adequate legal protection for the growing number of individuals with preclinical AD. Some PHI generated in preclinical AD trials has clinical significance, necessitating urgent evaluations and longitudinal monitoring in care settings. AD researchers are obligated to both respect the confidentiality of participants' sensitive PHI and facilitate providers' access to necessary information, often requiring disclosure of preclinical AD status. The AD research community must continue to develop ethical, participant-centered practices related to confidentiality and disclosure, with attention to sensitive information in the EHR. These practices will be essential for translation into the clinic and across health systems and society at large.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Gale SA, Heidebrink J, Grill J, et al. Preclinical Alzheimer Disease and the Electronic Health Record: Balancing Confidentiality and Care. Neurology. 2022. PMID: 36180237. doi:10.1212/WNL.0000000000201347

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。